BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22229973)

  • 1. Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease.
    Cushing M; Kawaguchi K; Friedman KD; Mark T
    Transfusion; 2012 Jul; 52(7):1535-41. PubMed ID: 22229973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD; Kunz D; Wirtz DC
    Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
    Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
    Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired von Willebrand disease and multiple myeloma: a case report of a breast cancer survivor.
    Jin N; Salahuddin FF; Nesbitt JA
    Blood Coagul Fibrinolysis; 2014 Dec; 25(8):890-3. PubMed ID: 24911454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
    Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M
    Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease.
    Geisen U; Heilmann C; Beyersdorf F; Benk C; Berchtold-Herz M; Schlensak C; Budde U; Zieger B
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):679-84. PubMed ID: 18282712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).
    Auerswald G; Eberspächer B; Engl W; Güthner C; Koksch M; Kreuz W; Nimtz A; Pindur G; Scheel H; Schreiber JD; Siekmann J; Turecek PL; Wolf HH
    Semin Thromb Hemost; 2002 Apr; 28(2):203-14. PubMed ID: 11992243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells.
    Richard C; Cuadrado MA; Prieto M; Batlle J; López Fernández MF; Rodriguez Salazar ML; Bello C; Recio M; Santoro T; Gomez Casares MT
    Am J Hematol; 1990 Oct; 35(2):114-7. PubMed ID: 2205095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study.
    Miesbach W; Krekeler S; Wolf Z; Seifried E
    Thromb Res; 2015 Mar; 135(3):479-84. PubMed ID: 25595881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous-infusion von Willebrand factor concentrate is effective for the management of acquired von Willebrand disease.
    Dane KE; Lindsley JP; Kickler T; Streiff MB; Moliterno A; Yui J; Naik R; Chaturvedi S
    Blood Adv; 2021 Jul; 5(14):2813-2816. PubMed ID: 34269797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
    Auerswald G; Kreuz W
    Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
    Windyga J; von Depka-Prondzinski M;
    Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: unexpected bleeding in the operating room: the role of acquired von Willebrand disease.
    Lison S; Dietrich W; Spannagl M
    Anesth Analg; 2012 Jan; 114(1):73-81. PubMed ID: 22025497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P).
    Thompson AR; Gill JC; Ewenstein BM; Mueller-Velten G; Schwartz BA;
    Haemophilia; 2004 Jan; 10(1):42-51. PubMed ID: 14962219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous infusion of von Willebrand factor and factor VIII after elective heart surgery in a 12-year-old girl with von Willebrand disease type 3.
    Kühne T; Imbach P; Marbet GA; Caliezi C; Devay J
    Pediatr Hematol Oncol; 1999; 16(6):551-6. PubMed ID: 10599096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired von Willebrand syndrome in patients with ventricular assist device or total artificial heart.
    Heilmann C; Geisen U; Beyersdorf F; Nakamura L; Benk C; Berchtold-Herz M; Trummer G; Schlensak C; Zieger B
    Thromb Haemost; 2010 May; 103(5):962-7. PubMed ID: 20352153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous infusion of human plasma-derived von Willebrand factor concentrate as an effective therapy in a patient with acquired von Willebrand disease.
    Patel SB; Rodgers GM
    Haemophilia; 2014 Nov; 20(6):e411-4. PubMed ID: 25333342
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.